Rhegmatogenous Retinal Detachment (RRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Rhegmatogenous retinal detachment (RRD) is a type of retinal detachment characterized by subretinal fluid between the neurosensory retina and the underlying retinal pigment epithelium. RRD typically occurs when a full-thickness defect in the neurosensory retina allows fluid to enter the subretinal space and separate the retina from the retinal pigment epithelium. The most common cause of RRD is the degeneration of the vitreous body, a gel-like substance that helps maintain the eye's shape. The vitreous body liquefies over time, creating a potential space for fluid to accumulate. RRD is more common in myopic individuals and those who have previously undergone cataract surgery. Patients with RRD may experience light flashes, floaters, or a visual "curtain" that obscures part of the visual field. The visual acuity can range from excellent to poor, depending on whether the macula remains attached. The presence of an afferent pupillary defect may indicate a large area of detachment. Various factors, including the liquefaction of the vitreous body, the presence of retinal breaks, and the adhesion mechanisms between the neurosensory retina and the retinal pigment epithelium, influence the development of RRD. The risk of RRD also varies based on factors such as gender, ethnicity, age, axial length, and prior eye surgery. Patients who have undergone cataract surgery are at an increased risk for developing RRD, with an estimated one in five in the UK being pseudophakic.

• The risk of developing RRD after phacoemulsification is estimated to be between 0.5% to 0.6%.

 

Thelansis’s “Rhegmatogenous Retinal Detachment (RRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rhegmatogenous Retinal Detachment (RRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Rhegmatogenous Retinal Detachment (RRD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Rhegmatogenous Retinal Detachment (RRD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Rhegmatogenous Retinal Detachment (RRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033